CJC-1295

A tetrasubstituted 29-residue synthetic peptide corresponding to the N-terminal GRF(1-29) sequence, bearing a C-terminal albumin-binding side chain.

Molecular Profile

Type
Synthetic peptide (acylated, 29 residues)
Molecular formula
C165H269N47O46
Molecular weight
~3,647 g/mol
CAS number
446262-90-4 (with DAC); 863288-34-0 (no-DAC)
Amino acids
29
Modification
Tetrasubstituted GRF(1-29) with a C-terminal Lys-linked maleimidopropionyl albumin-binding group (DAC); C-terminal amide.

Mechanism & Target Class

A 29-residue synthetic peptide corresponding to the N-terminal GRF(1-29) sequence of a 44-residue hypothalamic peptide. Cryo-EM studies of GRF(1-29)-class peptides bound to a class B GPCR-Gs complex resolve a continuous a-helical conformation in which the N-terminal segment inserts into the receptor transmembrane bundle and the central segment contacts the extracellular domain. Four amino-acid substitutions confer resistance to dipeptidyl-peptidase proteolysis; a C-terminal Lys-linked maleimidopropionyl (DAC) side chain reacts with serum albumin to confer reversible binding, extending circulatory half-life. A no-DAC variant (Mod GRF 1-29; ~3,368 g/mol; PubChem CID 91976842) is also offered.

Storage & Handling

Lyophilized
-20°C; typically stable 24-36 months desiccated and protected from light.
Handling
Avoid freeze-thaw; aliquot; protect from light and moisture. The DAC maleimide group is thiol-reactive.

Primary Database

PubChem CID 91971820 ↗

References (23)

  1. Reviews

    1

    Memdouh S, et al. (2021). Drug Test Anal

    DOI: 10.1002/dta.3183PubMed 34665524

  2. 2

    Halmos G, et al. (2025). Rev Endocr Metab Disord

    DOI: 10.1007/s11154-025-09952-xPubMed 39934495

  3. 3

    Halmos G, et al. (2023). Vitam Horm

    DOI: 10.1016/bs.vh.2023.06.004PubMed 37717982

  4. 4

    Montero-Hidalgo AJ, et al. (2025). Rev Endocr Metab Disord

    DOI: 10.1007/s11154-025-09943-yPubMed 39838154

  5. 5

    Dieguez C, et al. (2025). Rev Endocr Metab Disord

    DOI: 10.1007/s11154-025-09951-yPubMed 39913072

  6. 6

    Schally AV, et al. (2024). Rev Endocr Metab Disord

    DOI: 10.1007/s11154-024-09929-2PubMed 39592529

  7. 7

    Müller EE, et al. (1999). Physiol Rev

    DOI: 10.1152/physrev.1999.79.2.511PubMed 10221989

  8. Clinical

    8

    Teichman SL, et al. (2006). J Clin Endocrinol Metab

    DOI: 10.1210/jc.2005-1536PubMed 16352683

  9. 9

    Ionescu M, Frohman LA. (2006). J Clin Endocrinol Metab

    DOI: 10.1210/jc.2006-1702PubMed 17018654

  10. 10

    Stanley TL, et al. (2011). J Clin Endocrinol Metab

    DOI: 10.1210/jc.2010-1587PubMed 20943777

  11. Primary research

    11

    Timms M, et al. (2019). Drug Test Anal

    DOI: 10.1002/dta.2599PubMed 30938069

  12. 12

    Timms M, et al. (2019). Drug Test Anal

    DOI: 10.1002/dta.2554PubMed 30489688

  13. 13

    Henninge J, et al. (2010). Drug Test Anal

    DOI: 10.1002/dta.233PubMed 21204297

  14. 14

    Sackmann-Sala L, et al. (2009). Growth Horm IGF Res

    DOI: 10.1016/j.ghir.2009.03.001PubMed 19386527

  15. 15

    Alba M, et al. (2006). Am J Physiol Endocrinol Metab

    DOI: 10.1152/ajpendo.00201.2006PubMed 16822960

  16. 16

    Jetté L, et al. (2005). Endocrinology

    DOI: 10.1210/en.2004-1286PubMed 15817669

  17. 17

    Alba M, et al. (2005). Endocrinology

    DOI: 10.1210/en.2004-1044PubMed 15564325

  18. 18

    Bongers J, et al. (1992). Biochim Biophys Acta

    DOI: 10.1016/0167-4838(92)90317-7PubMed 1353684

  19. 19

    Kato M, Sakuma Y. (1997). Endocrinology

    DOI: 10.1210/endo.138.12.5589PubMed 9389488

  20. 20

    Zhou F, et al. (2020). Nat Commun

    DOI: 10.1038/s41467-020-18945-0PubMed 33060564

  21. 21

    Thomas A, et al. (2012). Methods

    DOI: 10.1016/j.ymeth.2011.08.009PubMed 21871962

  22. 22

    Thomas A, et al. (2024). J Mass Spectrom

    DOI: 10.1002/jms.4996PubMed 38197510

  23. 23

    Uçaktürk E, Nemutlu E. (2026). J Pharm Biomed Anal

    DOI: 10.1016/j.jpba.2025.117207PubMed 41138283